Now important are gender differences in pharmacokinetics?

被引:342
作者
Meibohm, B
Beierle, I
Derendorf, H
机构
[1] Univ Tennessee, Dept Pharmaceut Sci, Memphis, TN 38163 USA
[2] Univ Tennessee, Coll Pharm, Dept Clin Pharm, Memphis, TN USA
[3] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
关键词
D O I
10.2165/00003088-200241050-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gender-related differences in pharmacokinetics have frequently been considered as potentially important determinants for the clinical effectiveness of drug therapy. The mechanistic processes underlying gender-specific pharmacokinetics can be divided into molecular and physiological factors. Major molecular factors involved in drug disposition include drug transporters and drug-metabolising enzymes. Men seem to have a higher activity relative to women for the cytochrome P450 (CYP) isoenzymes CYPIA2 and potentially CYP2E1, for the drug efflux transporter P-glycoprotein, and for some isoforms of glucuronosyltransferases and sulfotransferases. Women were suggested to have a higher CYP2D6 activity. No major gender-specific differences seem to exist for CYP2C19 and CYP3A. The often-described higher hepatic clearance in women compared with men for substrates of CYP3A and P-glycoprotein, such as erythromycin and verapamil, may be explained by increased intrahepatocellular substrate availability due to lower hepatic P-glycoprotein activity in women relative to men. Physiological factors resulting in gender-related pharmacokinetic differences include the generally lower bodyweight and organ size, higher percentage of body fat, lower glomerular filtration rate and different gastric motility in women compared with men. Although gender disparity in pharmacokinetics has been identified for numerous drugs, differences are generally only subtle. For a few drugs, e.g. verapamil, beta-blockers and selective serotonin reuptake inhibitors, gender-related differences in pharmacokinetics have been shown to result in different pharmacological responses, but their clinical relevance remains unproven. In contrast, gender differences of clinical importance have clearly been identified for pharmacodynamic processes such as QTc prolongation, and intensive future research efforts are needed to assess the full scope and impact of pharmacodynamic gender disparity on applied pharmacotherapy.
引用
收藏
页码:329 / 342
页数:14
相关论文
共 160 条
  • [1] HUMAN LIVER DEHYDROEPIANDROSTERONE SULFOTRANSFERASE - NATURE AND EXTENT OF INDIVIDUAL VARIATION
    AKSOY, IA
    SOCHOROVA, V
    WEINSHILBOUM, RM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (05) : 498 - 506
  • [2] Biochemical, cellular, and pharmacological aspects of the multidrug transporter
    Ambudkar, SV
    Dey, S
    Hrycyna, CA
    Ramachandra, M
    Pastan, I
    Gottesman, MM
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 : 361 - 398
  • [3] [Anonymous], 2000, Fed Regist, V65, P34963
  • [4] PHARMACOKINETIC DRUG-INTERACTIONS WITH ORAL-CONTRACEPTIVES
    BACK, DJ
    ORME, MLE
    [J]. CLINICAL PHARMACOKINETICS, 1990, 18 (06) : 472 - 484
  • [5] The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: A comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate
    Bartoli, A
    Xiaodong, S
    Gatti, G
    Cipolla, G
    Marchiselli, R
    Perucca, E
    [J]. THERAPEUTIC DRUG MONITORING, 1996, 18 (05) : 586 - 591
  • [6] Beierle I, 1999, INT J CLIN PHARM TH, V37, P529
  • [7] Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
    Benet, LZ
    Izumi, T
    Zhang, YC
    Silverman, JA
    Wacher, VJ
    [J]. JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) : 25 - 31
  • [8] Greater quinidine-induced QTc interval prolongation in women
    Benton, RE
    Sale, M
    Flockhart, DA
    Woosley, RL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (04) : 413 - 418
  • [9] CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST
    BERTILSSON, L
    CARRILLO, JA
    DAHL, ML
    LLERENA, A
    ALM, C
    BONDESSON, U
    LINDSTROM, L
    DELARUBIA, IR
    RAMOS, S
    BENITEZ, J
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) : 471 - 473
  • [10] THE INFLUENCE OF ENVIRONMENTAL AND GENETIC-FACTORS ON CYP2D6, CYP1A2 AND UDP-GLUCURONOSYLTRANSFERASES IN MAN USING SPARTEINE, CAFFEINE, AND PARACETAMOL AS PROBES
    BOCK, KW
    SCHRENK, D
    FORSTER, A
    GRIESE, EU
    MORIKE, K
    BROCKMEIER, D
    EICHELBAUM, M
    [J]. PHARMACOGENETICS, 1994, 4 (04): : 209 - 218